Optison (Perflutren)

Perflutren consists of microscopic gas‑filled microbubbles that remain within the vascular compartment after intravenous injection. These microbubbles have a high acoustic impedance difference compared with surrounding tissues, causing them to reflect ultrasound waves strongly and generate bright echoes that improve image contrast during scanning.

The dose of Optison is determined by the prescribing physician based on the specific imaging protocol and patient characteristics. It is administered intravenously as a bolus injection, and the exact volume and timing are tailored to achieve optimal contrast enhancement for the intended ultrasound study.

Safety data for Optison in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential diagnostic benefit outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Optison, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

The primary alternative to Optison is Definity (perflutren lipid microsphere). Both agents provide microbubble contrast for ultrasound, but Optison uses a protein‑based shell while Definity uses a lipid shell, which may affect stability and imaging duration. Clinical choice often depends on physician preference, specific imaging protocols, and regulatory approvals in the target market.

Optison must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the suspension. Before use, gently invert the vial to ensure uniform suspension of the microbubbles, following the manufacturer’s preparation instructions.

Optison is administered as an intravenous bolus injection, typically through a peripheral vein. The injection is performed by a qualified healthcare professional under continuous monitoring of vital signs. The timing of the injection is coordinated with the ultrasound equipment to capture optimal contrast enhancement during the imaging sequence.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, cardiopulmonary arrest, and profound hypotension. These events are rare but require immediate medical intervention. Clinicians should be prepared to manage allergic reactions and monitor patients closely during and after administration.

Optison is contraindicated in patients with a known hypersensitivity to perflutren, any component of the formulation, or other ultrasound contrast agents. It should also be avoided in individuals who have experienced severe allergic reactions to similar products, and used with caution in patients with unstable cardiac conditions.